API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ottawa Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021